Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and showing promise with 5008X dialysis system adoption and value-based care expansion. However, the company faces significant headwinds including U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation concerns. The company maintains a Zacks Rank #3 (Hold) rating with consensus expectations for 2.7% revenue growth but 5.4% earnings decline in 2026.

Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.

Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and expanding high-volume HDF and 5008X dialysis systems. However, the company faces significant challenges including persistent U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation-related cost risks. The company maintains a Zacks Rank #3 (Hold) with consensus 2026 earnings expected to decline 7% year-over-year.

A new analysis by Spherix Global Insights reveals that access barriers, not efficacy issues, are limiting Xphozah (tenapanor) uptake in the dialysis hyperphosphatemia market. Nephrologists report they would nearly triple Xphozah use without reimbursement and coverage obstacles. However, the drug faces persistence challenges with gastrointestinal tolerability causing discontinuation rates to double to 8%. The findings also show physicians significantly overestimate phosphorus control and combination therapy use among patients. As the TDAPA reimbursement program expires at the end of 2026, phosphate-lowering therapies will face a flattened competitive landscape.

The global urology devices market is valued at USD 39.23 billion in 2025 and is projected to reach USD 80.0 billion by 2035, growing at a CAGR of 7.35%. Growth is driven by rising demand for robotic-assisted surgery, kidney disease treatment, and minimally invasive procedures. North America leads the market while Asia Pacific records the fastest growth.

The U.S. arteriovenous fistula devices market is projected to grow from $112 million in 2025 to $120 million by 2033, driven by rising end-stage renal disease cases and increasing demand for advanced vascular access solutions.

Quest Diagnostics reported strong Q1 2025 results, with revenue and earnings beating estimates. The company reaffirmed its full-year guidance and announced strategic acquisitions and partnerships, fueling confidence in its outlook.

The global wearable artificial organs market is expected to grow significantly from $11.17 billion in 2024 to $64.19 billion by 2035, driven by government initiatives, technological advancements, and patient preference for non-invasive solutions. North America and Asia Pacific are expected to be the key growth regions.

The report provides a comprehensive analysis of the China infusion systems market, including infusion pumps and infusion pump disposables, with data from 2018 to 2033. It covers key market information, company profiles, pipeline products, and recent developments.

The U.S. compounding pharmacies market is expected to grow at a CAGR of 4.06% from 2023 to 2029, driven by the growing demand for compounded bioidentical menopausal hormone therapy among women and the increasing adoption of advanced technologies in the industry.

The global hemodialysis and peritoneal dialysis market is projected to reach a value of USD 142.97 Billion by 2031, growing at a CAGR of 6.5% during the forecast period. The increasing prevalence of chronic kidney disease and the need for innovative dialysis technologies are driving the market growth.

The global hemodialysis and peritoneal dialysis market is expected to reach a value of USD 142.97 Billion by 2031, driven by the increasing prevalence of chronic kidney disease and the need for innovative dialysis technologies.